BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MARGENZA (margetuximab-cmkb) by MacroGenics is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2020.
Drug data last refreshed 19h ago
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
MacroGenics
MD - Rockville
Worked on MARGENZA at MacroGenics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.